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Abstract
Background: This study evaluated the treatment results of lymph node (LN) oligo-recurrence in esophageal cancer
patients treated with salvage radiotherapy (RT) in a multi-institutional retrospective study.
Methods: Eligibility criteria for this retrospective analysis were: the primary lesion of esophageal cancer was
controlled; from one to five LN recurrences; total RT dose ≥45 Gy to exclude palliative RT; without recurrence other
than LN; and salvage RT for LN recurrence was given between January 2000 and April 2015. The median follow-up
time for the 93 living patients was 29.6 months.
Results: Two hundred thirty-seven patients were matched in five hospitals. The 3-year overall survival (OS) was
37%, local control was 45%, progression-free survival was 24%, and esophageal cancer-specific survival was 42%. On
univariate analysis for OS, combined chemotherapy (p = 0.000055), disease-free interval (DFI) ≥12 months (p = 0.
0013), LN max diameter ≤22 mm (p = 0.0052), and Karnofsky performance status ≥80% (p = 0.030) were associated
with a significantly better prognosis. On multivariate analysis, significant differences were seen for combined
chemotherapy (p = 0.000018), DFI (p = 0.0027), and LN max diameter (p = 0.018).
Conclusions: LN oligo-recurrence following treatment for esophageal cancer was not a terminal-stage event.
Moreover, cure may be possible by chemoradiation therapy with a long DFI (≥12 months) and small size (≤22 mm).
Keywords: Esophageal cancer, Oligo-recurrence, Oligometastases, Salvage chemoradiation therapy, Salvage radiation
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Background
Lymph node (LN) recurrence from esophageal cancer
after surgery is one of the main types of treatment fail-
ure [1–3]. According to several reports, 42.5–52.4% of
operated patients develop recurrence, and these patients’
prognosis remains poor [4–8]. The median survival time
(MST) of all postoperative recurrent esophageal cancers
including loco-regional, distant, and combined recur-
rence has been shown to be 6.0–8.2 months [1, 5].
Although some analyses indicated that treatment of
locoregional recurrence (LR) prolonged survival regard-
less of the treatment type, the outcome of patients
treated with chemotherapy (CTx) alone was significantly
worse than for patients treated with other intensive ther-
apies [9]. Therefore, CTx alone is usually reserved for
patients with distant metastases.
On the other hand, radiotherapy (RT), chemoradiation
therapy (CRT), or lymphadenectomy have been used in
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treating LR. These treatments have had a beneficial
symptomatic effect for a significant proportion of these
patients, and it is possible to obtain long-term survival
in some patients [9–12]. Cancer patients with ≤ 5 meta-
static or recurrent lesions with controlled primary
lesions can be considered as having "oligo-recurrence".
The concept of oligo-recurrence was proposed and
defined by Niibe et al. in 2006 [13–15]. Local therapy
was occasionally added to these recurrent sites with or
without systemic therapy. However, the outcome of
salvage RT and prognostic factors for LN oligo-
recurrence of esophageal cancer have not been studied
extensively. In some institutions, local therapy was given
to patients without controlled primary lesions, but this
was based on the assumption of radical resection for
primary lesions after local therapy for recurrence.
For LN oligo-recurrence after primary definitive CRT,
salvage surgery is first considered, and, when surgery is
not indicated, salvage CRT or stereotactic radiotherapy
is performed. Some researchers [16, 17] have also advo-
cated that, for clinically isolated locoregional recurrence
or clinically solitary solid organ metastasis patients,
surgical therapy with or without systemic therapy should
be considered first after diagnosis of recurrence, al-
though it may not be a universal approach. Additionally,
they have argued that, when surgery was impossible
or contraindicated, the combination of CRT appeared
to be superior to chemotherapy alone or radiotherapy
alone [18, 19]. In some institutions, for inoperable LN
recurrence after radical surgery or definitive CRT,
curative therapy is abandoned, and palliative CTx or
best supportive care is selected.
The purpose of this retrospective study was to assess the
efficacy of salvage RT or CRT for inoperable LN recurrence
after primary curative therapy for esophageal cancer.
Methods
Subjects
The eligibility criteria for this retrospective analysis were
as follows: a) the primary lesion of esophageal cancer was
controlled; b) from 1–5 LN recurrences; c) total RT dose
of ≥45 Gy in order to exclude palliative RT; d) without re-
currence other than LN; and e) salvage RT or CRT for LN
recurrence was given between January 2000 and April
2015. The eligibility criteria did not include with or with-
out combined CTx, the kind of initial curative therapy, the
disease-free interval (DFI), recurrent LN location, LN max
diameter, age, Karnofsky performance status (KPS), and
the histopathological type of primary tumor.
The DFI was defined as the interval between initial
therapy for the primary lesion and the date of identifica-
tion of LN recurrence. This was the endoscopic sub-
mucosal dissection date, the operation date independent
of perioperative CTx, or the starting date of initial CRT.
The reason why the 11 patients with stage IV disease
received curative treatment (surgery in eight patients
and CRT in three) was that these patients had only
supraclavicular, para-aortic, or hilar LN metastasis, and
cure was considered possible. These stages were classi-
fied based on the UICC/AJCC TNM system version 7.
Statistical analysis
Survival curves were prepared using the Kaplan-Meier
method, and the p value on univariate analysis for over-
all survival (OS) was calculated by the log-rank test. The
95% confidence interval (CI) was calculated using
Greenwood’s formula. The significance level was set at
5%. The events were defined as any death for OS, local
recurrence within the radiation field for local control,
any death and any relapse for relapse-free survival, and
death from esophageal cancer for esophageal cancer-
specific survival. Multivariate analysis for OS was per-
formed with a Cox proportional hazards model, and the
variables were selected by the stepwise method using the
Bayesian Information Criterion (BIC). The Bonferroni
correction was used for multiple comparisons; in other
words, the significance level was set as 5% divided by the
number of variables in the multivariate analysis.
Results
Patient and tumor characteristics
A total of 237 patients who matched the study definition
of oligo-recurrence were treated by CRT or RT alone in
five Japanese hospitals. The median age was 66 years
(range, 36–87 years). The male-to-female ratio was
207:30. The ratio of KPS ≥90% to <90% was 154:83.
Primary histopathology was squamous cell carcinoma
(SCC) in 231 patients, adenocarcinoma or adeno-
squamous cell carcinoma in three patients, and others in
three patients. Clinical stages I, II, III, and IV at the
initial curative therapy were seen in 34, 89, 103, and 11
patients, respectively. The primary tumor location was
cervical in 10 patients (whose primary therapy was
surgery in 9 patients and CRT in one patient), upper
thoracic in 22 patients, middle thoracic in 140 patients,
and lower thoracic plus gastric-esophageal junction in
65 patients. The primary therapy was endoscopic sub-
mucosal dissection in five patients, radical surgery in
219 patients (including preoperative chemoradiation in
three patients, preoperative CTx in two patients, postop-
erative CTx in one patient), and definitive CRT in 13
patients. The median DFI was 11.9 months (range, 1.1–
149.1 months). The number of LN recurrences was one
in 161 patients (68%), two in 31 patients, three in 29 pa-
tients, four in seven patients, and five in five patients.
The median maximum LN diameter (MLD), which was
defined as the greatest transverse diameter in the axial
plane, was 22 mm (range, 5–106 mm). The location of
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recurrent LN metastasis was loco-regional only in 144
patients (60.8%) and distant regions only, such as neck,
supraclavicular, abdominal para-aortic, or hilar LNs, in 66
patients (27.8%); 27 patients (11.4%) had both loco-
regional and distant region involvement. The median total
radiation dose was 60 Gy (range, 45–70 Gy). Median over-
all treatment time was 43 days (range, 11–57 days).
Radiation therapy was involved-field in 170 patients,
extended-field including prophylactic irradiation in 62
patients, and stereotactic body radiotherapy of 50 Gy in
10 fractions in five patients. Systemic CTx was adminis-
tered concurrently to 199 patients (84%), but two patients
received it sequentially following RT. The regimen in-
cluded an FP regimen (5-fluorouracil and cisplatin) in 65
patients, nedaplatin plus 5-fluorouracil in 102 patients, S1
alone in 17 patients, docetaxel alone in nine patients, a
DCF regimen (docetaxel, cisplatin, and 5-fluorouracil) in
two patients, and others in four patients.
First failure site
The first failure site after this definitive salvage RT was
lung in 38 patients, liver in 19 patients, bone in 10
patients, other distant organs in 11 patients, distant LN
in 47 patients, and locoregional LN in 61 patients (31
patients within field and 30 patients outside field). When
taken together, in-field recurrence of salvage RT oc-
curred in 31 patients (16.7%), and out-of-field recurrence
was seen in 155 patients (83.3%).
Survival
The median follow-up time for the 93 living patients
was 29.6 months (range, 1.9–154.0 months). The overall
follow-up was 15.0 months (range, 0.2–154 months),
and 12 patients were lost to follow-up. The 3-year OS
was 36.7% (95% CI: 29.8–43.6%), local control was 45.1%
(95% CI: 37.3–52.6%), relapse-free survival was 24.1%
(95% CI: 18.6–30.1%), and esophageal cancer-specific
survival was 41.5% (95% CI: 34.1–48.7%). The MST was
21.6 months (95% CI: 18.0–28.5 months).
Univariate analysis of OS (Table 1)
The 3-year OS was 39.7% (95% CI: 32.1–47.3%) with
CRT and 20.8% (95% CI: 8.3–37.0%) with RT alone (p =
0.000055, log-rank test) (Fig. 1). The 3-year OS was 45.9%
(95% CI: 35.6–55.6%) for DFI ≥12 months and 27.3% (95%
CI: 18.6–36.6%) for DFI <12 months (p = 0.0013) (Fig. 2).
The 3-year OS was 30.2% (95% CI: 20.1–39.9%) for
MLD >22 mm and 42.1% (95% CI: 32.3–51.6%) for
MLD ≤ 22 mm (p = 0.0052) (Fig. 3). The KPS 80–100
group achieved a 3-year OS of 43.1%, compared to
11.9% for KPS ≤70 (p = 0.030). Age >66 vs. ≥66 years
(p = 0.76), KPS >90% vs. ≤90% (p = 0.11), number of
LN recurrences mono vs. multiple (p = 0.44), LN loca-
tion locoregional vs. distant (p = 0.41), serum SCC
antibody value >2 mg/mL vs. ≤2 mg/mL (p = 0.42),
and histopathological type SCC vs. others (p = 0.55)
were not significant prognostic factors.
Multivariate analysis of OS
On multivariate analysis by the BIC stepwise method
(Table 2), multiple factors such as age, KPS, number of
LNs, LN location, histopathological type, serum SCC
antibody value, CTx, DFI, and LN max diameter were
included. CTx (HR = 0.40 and p = 0.000018), DFI (HR =
0.60 and p = 0.0027), and LN max diameter (HR = 0.65
and p = 0.012) were significant.
Table 1 Univariate analysis of overall survival
Factors No. MST 95% CI p value
Age, y
> 66 109 21.5 15.3–32.6 0.76
≤ 66 128 21.6 14.6–29.1
Serum SCC antibody
> 2 ng/mL 65 23.0 10.0–29.0 0.42
≤ 2 ng/mL 172 21.6 18.0–30.6
Combined CTX
Without 38 10.8 6.3–21.5 0.000055
With 199 26.0 18.5–32.8
DFI
≤ 12 mo 119 14.5 12.8–18.8 0.0013
> 12 months 118 30.6 23.2–42.0
DFI
≤ 24 months 183 18.0 14.2–23.2 0.0041
> 24 months 54 41.0 26.0–116.0
KPS
< 90% 83 14.6 12.3–28.0 0.11
≥ 90% 154 26.0 18.0–32.8
No. of LN metastasis
Mono 165 26.0 17.8–33.0 0.44
Multiple 72 18.8 14.6–28.5
LN max diameter
> 22 mm 109 15.7 13.5–23.5 0.0052
≤ 22 mm 128 29.1 19.8–41.1
LN location
Distant 90 20.2 14.2–27.0 0.41
Locoregional 147 26.4 18.0–34.3
Histopathology
SCC 231 23.0 18.0–28.5 0.55
Others 6 15.0 12.0-NA
Abbreviation: No. number, MST median survival time, CI confidence interval,
SCC squamous cell carcinoma, CTX chemotherapy, DFI disease-free interval,
KPS Karnofsky performance status, LN lymph node
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The number of patients with all of (a) treated with
CRT, (b) DFI of not less than 12 months, and (c) LN
max diameter of not more than 22 mm was 56 (24%).
The 2-y OS and 3-y OS of these patients were 64.9%
(95% CI: 50.1–76.3%) and 55.2% (95% CI: 40.0–68.0%),
respectively, and the MST was 43.4 months (95% CI:
26.5-NA months).
Toxicity
Eleven patients (4.6%) experienced acute or late non-
hematologic adverse events of grade 3 or greater accord-
ing to the Common Terminology Criteria for Adverse
Events (CTCAE) v4.0, including: grade 4 cardiac
tamponade at 4.6 months after the completion of RT;
grade 5 drug-induced interstitial pneumonia at 0.3 months;
grade 4 hyperglycemia during treatment; grade 5 pleural
effusion at 13.5 months; grade 3 anastomotic stenosis at
1.4 months; grade 5 mediastinal-bronchial fistula at
2.6 months; grade 5 esophageal bleeding at 3.3 months;
grade 4 esophagobronchial fistula during treatment; grade
5 gastric ulcer bleeding at 0.2 months; grade 4 fistula of a
gastric tube at 15.4 months; and grade 4 gastric tube to
bronchial fistula at 1.0 months.
Discussion
According to previous studies of RT or CRT for pa-
tients with postoperative LR of esophageal cancer, the
median MST of 13 studies was 13.6 months (range,
7–24.3 months), and the median 2-y OS was 25%
(range, 10.5–51%) [9–11, 20–25]. Among these stud-
ies, Jingu et al. [12] reported the long-term results of
CRT for postoperative LR in their prospective phase
Fig. 1 Overall survival curves for CRT and RT alone
Fig. 2 Overall survival curves for disease-free
interval < 12 months and≥ 12 months
Fig. 3 Overall survival curves for recurrent lymph node maximum
diameter > 22 mm and≤ 22 mm
Table 2 Multivariate analysis of overall survival by the stepwise
method
Factors HR Lower Upper p value
95% CI 95% CI
CTX
Without/with 0.40 0.27 0.84 0.000018
DFI
≤/> 12 months 0.60 0.43 0.84 0.0027
LN max diameter
>/≤ 22 mm 0.65 0.43 0.84 0.012
Abbreviation: HR hazard ratio, CI confidence interval, CTX chemotherapy, DFI
disease-free interval, LN lymph node
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II study. A total of 30 patients were treated for post-
operative LR with RT (60 Gy in 30 fractions) com-
bined with CTx consisting of two cycles of nedaplatin
(70 mg/m2/day) and 5-fluorouracil (500 mg/m2/day,
for 5 days). With a median observation period of
72 months, the 3-y OS was 38.4%, with an MST of
21.0 months. Three-year relapse-free survival was 29.3%,
and the 3-y irradiated-field control rate was 71.5%.
Although the present results should be interpreted with
caution because of the short observation period, the MST
of 21.6 months and the 3-y OS of 36.7% can be looked
upon as favorable and encouraging.
Several prognostic factors have been reported. For
example, high RT dose, younger age, non-anastomotic
recurrence, good performance status, single LN recur-
rence, and single recurrent region predicted better out-
comes [9–11, 20, 21, 24–26]. The optimal RT dose for
LR has not been established. Some studies demonstrated
that a high RT dose was a better prognostic factor [10,
11, 25]. Zhang et al. [11] reported that an RT dose of
more than 60 Gy showed a trend to improving OS. In
the present study, univariate analyses showed that the
significant prognostic factors for OS were CRT, DFI
≥12 months, MLD ≤22 mm, and KPS ≥80%.
In the study of Jingu et al. [12, 24], patients who had
LN metastases in multiple regions, such as mediastinal
and supraclavicular or mediastinal and abdominal LNs,
or metastases to many LNs in one region were irradiated
by a T-shaped field (including the bilateral supraclavicu-
lar, mediastinal, and abdominal regions). Especially with-
out combined chemotherapy, prophylactic irradiation
may be needed at some level in view of the involvement
of the lymphatic system for such patients with LN recur-
rence. In the present study, there was no difference in
OS between elective lymph node irradiation and
involved-field radiotherapy.
The present study has several limitations associated
with its retrospective design. This study could not dem-
onstrate a survival benefit of salvage RT or CRT com-
pared to other treatment modalities such as CTx-alone.
According to the previous reports of life-prolonging
chemotherapy alone for esophageal M1 patients, the me-
dian survival time was 10.0–15.5 months [16, 17, 27,
28]. In the present study, the MST was 21.6 months,
and the lower value of the 95%CI was 18.0 months.
Based on this result, at least the combination of CTx
with RT for oligo-recurrence in the LNs from esophageal
cancer is strongly recommended, although the inclusion
criteria of this study were quite different from esopha-
geal M1 chemotherapy trials in which patients with
poorer risk were also included. There were some selec-
tion biases: the selection of primary therapy and/or
salvage therapy was different among these five institu-
tions; whether curative salvage CRT was performed for
recurrences without controlling the primary lesion; and
the non-uniformity of the combined CTx regimen, RT
dose, indication of stereotactic body radiotherapy, and
follow-up method by institutions.
Depypere et al. [19] and Nakamura et al. [9] advocated
that the combination of CRT appeared to be superior to
CTx alone or RT alone for recurrent disease after esopha-
gectomy, and the addition of CTx seems to play a crucial
role in this disease state. In this study, RT alone and
stereotactic radiotherapy alone were performed only for
patients to whom CTx could not be delivered due to poor
PS, high age, or impaired renal function.
In the present study, 60 Gy was given to 157 patients
(78.9%) and 50/50.4 Gy was given to 21 patients (10.6%)
of 199 patients treated with CRT. In the primary treat-
ment, 50–50.4 Gy of RT is standard for patients treated
with definitive CRT [29], although higher doses may be
appropriate for tumors of the cervical esophagus, espe-
cially when surgery is not planned. However, in Japan,
many hospitals have still adopted 60 Gy in place of 50–
50.4 Gy, and 60 Gy represented a large percentage in the
present study as well.
According to the above-cited study by Nakamura et al.
[9], the 3-y cumulative OS after lymphadenectomy for
19 patients with LN recurrence of esophageal carcinoma
after curative resection was 50.7%. In the present study,
the 3-y OS was 36.7% (95% CI: 29.8–43.6%), and this
value seemed to be slightly inferior to Nakamura’s result,
although the treatment-related toxicity could not be
compared.
Conclusions
Oligo-recurrence involving LNs following treatment for
esophageal cancer does not appear to be a terminal-
stage event, unlike other distant metastases. Moreover,
cure may be possible by chemoradiation therapy with a
long DFI (≥12 months) and a small size (≤22 mm).
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